Missed Nvidia? Missed Tesla? Marketing AI Could Be Next
A rising AI marketing platform is now available through Reg A+ at $0.85 per share, aiming to become a fresh growth ve...
Automatic Rebalancing Fifo Vs Specific Share Lots
Automatic rebalancing can use FIFO or specific share lots to determine gains. This intro contrasts methods and outlines tax effects.
18,554 articles
Housing Paradox: Banning Institutional Investors at Risk
A nationwide policy debate over banning institutional single-family rentals risks tightening rental supply and liftin...
Live Updates: Will Marvell Beat Q4 Earnings Tonight
Marvell Technology is due to report Q4 results after the bell, with investors watching whether the company can beat e...
Daryl Hannah Breaks 30-Years of Silence Over JFK Jr
Daryl Hannah publicly refutes decades of rumors about her life with JFK Jr., spotlighting how reputational storms rip...
If You Haven’t Already Bought Micron, Here’s Why
Micron Technology races higher on AI memory demand and supply tightness. This piece outlines why investors may consid...
Short Sellers Betting Against Intel Intensifies in Dow
Intel remains the Dow's most shorted stock as fresh data show rising short interest amid continued cash burn in the f...
Oil Went Over $100 Again as Hormuz Uncertainty Deepens
Oil surged past the $100 mark again on March 12, 2026, after the U.S. signaled limits to protecting the Strait of Hor...
Renewable Energy Stock Year: A 54% Rally Signals Confidence
A bold bet on a geothermal energy company highlights a broader shift in the renewable energy stock year. Learn what i...
Best Biotech Stocks Right Now: Growth Leaders to Watch
Biotech stocks rally as late-stage trial data and regulatory milestones boost investor confidence. Analysts say the b...
Vertex Pharmaceuticals Heading $600? A Stock Outlook
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Should Metals Company Stock Be a Bargain Below $7?
As demand for critical minerals grows, The Metals Company (TMC) sits at a pivotal price point. This guide explores wh...
Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status